IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

Shin Etsu Chemical / Equity Capital Markets

<ul>
<li>Since the announcement of the US$1.0 billion secondary offering, <a href="https://www.smartkarma.com/entities/shin-etsu-chemical-co-ltd" target="_blank" data-smartkarma-citation="entities:4481:1" rel="noopener">Shin Etsu Chemical (4063 JP)</a>’s shares have declined 6.3% to the undisturbed price of JPY5,476 per share (27 January).</li>
<li>It is instructive to look at recent large Japanese placements to understand the potential trading pattern. Shin Etsu's share decline is lower than the median of recent large placements.</li>
<li>The offering will likely be priced on 4 February. The average large Japanese placement tends to generate positive returns.</li>
</ul>


Since the announcement of the US$1.0 billion secondary offering, Shin Etsu Chemical (4063 JP)’s shares have declined 6.3% to the undisturbed price of JPY5,476 per share (27 January).
It is instructive to look at recent large Japanese placements to understand the potential trading pattern. Shin Etsu's share decline is lower than the median of recent large placements.
The offering will likely be priced on 4 February. The average large Japanese placement tends to generate positive returns.


Shin Etsu Chemical (4063 JP): The Current Playbook

<ul>
<li>
<a href="https://www.smartkarma.com/entities/kandenko-co-ltd" target="_blank" data-smartkarma-citation="entities:3726:1" rel="noopener">Kandenko Co Ltd (1942 JP)</a> has announced a secondary offering of 22.8 million shares (26.2 million including overallotment), worth around US$0.8 billion (US$1.0 billion including overallotment).</li>
<li>The timing is opportunistic as the shares are up 159% in the last 12 months. Notably, the placement was announced post-close after the full-year results were <a href="https://www.kandenko.co.jp/en/docs/3Notice%20of%20Revision%20to%20Financial%20Results%20and%20Dividend%20Forecasts.pdf" target="_blank" rel="noopener">upgraded intraday</a>.</li>
<li>The offering as a percentage of outstanding shares and ADV is below average compared to recent large placements. A ToSTNeT-3 repurchase (up to JPY30 billion) will partly mitigate the impact.</li>
</ul>



Kandenko Co Ltd (1942 JP) has announced a secondary offering of 22.8 million shares (26.2 million including overallotment), worth around US$0.8 billion (US$1.0 billion including overallotment).
The timing is opportunistic as the shares are up 159% in the last 12 months. Notably, the placement was announced post-close after the full-year results were upgraded intraday.
The offering as a percentage of outstanding shares and ADV is below average compared to recent large placements. A ToSTNeT-3 repurchase (up to JPY30 billion) will partly mitigate the impact.


Kandenko (1942 JP): A US$1.0 Billion Secondary Offering

<ul>
<li>
<a href="https://www.smartkarma.com/entities/shin-etsu-chemical-co-ltd" target="_blank" data-smartkarma-citation="entities:4481:1" rel="noopener">Shin Etsu Chemical (4063 JP)</a> has announced a secondary offering of up to 23.7 million shares (27.2 million including overallotment), worth around US$0.8 billion (US$1.0 billion including overallotment).</li>
<li>The goal of the secondary offering seems to be to facilitate the exits of several shareholders and improve liquidity.</li>
<li>The offering as a percentage of outstanding shares and ADV is small compared to recent large placements. An ongoing JPY100 billion share buyback will further mitigate the impact.</li>
</ul>



Shin Etsu Chemical (4063 JP) has announced a secondary offering of up to 23.7 million shares (27.2 million including overallotment), worth around US$0.8 billion (US$1.0 billion including overallotment).
The goal of the secondary offering seems to be to facilitate the exits of several shareholders and improve liquidity.
The offering as a percentage of outstanding shares and ADV is small compared to recent large placements. An ongoing JPY100 billion share buyback will further mitigate the impact.


Shin Etsu Chemical (4063 JP): A US$1.0 Billion Secondary Offering

Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/nihon-kohden-corp" target="_blank" data-smartkarma-citation="entities:7668:1" rel="noopener">Nihon Kohden (6849 JP)</a> reiterated previous guidance for overall revenue to be ¥240B in FY26 (+6.5% YoY). Domestic sales have been slightly revised downwards while overseas revenue witnessed upward revision.</li>
<li>North America to be near-term growth driver. H1FY26 revenue from North America increased 16% YoY to ¥22.3B. Expected to grow 18% YoY to ¥49.5B (55% of overseas sales) in FY26.</li>
<li>Nihon Kohden has a sustainable long-term growth prospect. The three-year business plan further enhances conviction on the same.</li>
</ul>



Nihon Kohden (6849 JP) reiterated previous guidance for overall revenue to be ¥240B in FY26 (+6.5% YoY). Domestic sales have been slightly revised downwards while overseas revenue witnessed upward revision.
North America to be near-term growth driver. H1FY26 revenue from North America increased 16% YoY to ¥22.3B. Expected to grow 18% YoY to ¥49.5B (55% of overseas sales) in FY26.
Nihon Kohden has a sustainable long-term growth prospect. The three-year business plan further enhances conviction on the same.


Nihon Kohden (6849 JP): Stable Japan, Growing US; ¥5B Share Buyback Plan Augurs Well

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analysed the earning revision of component stocks of M-Japan in the past month.</li>
<li>We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.</li>
<li>We highlighted EPS revision on Toyota Motor, SoftBank, Rakuten, Kioxia, Sony Financial, Ebara, Honda Motor, Softbank, Ebara, Kioxia, Toyota Motor, Honda Motor, Sony Financial, Rakuten.</li>
</ul>


We analysed the earning revision of component stocks of M-Japan in the past month.
We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.
We highlighted EPS revision on Toyota Motor, SoftBank, Rakuten, Kioxia, Sony Financial, Ebara, Honda Motor, Softbank, Ebara, Kioxia, Toyota Motor, Honda Motor, Sony Financial, Rakuten.


M-Japan Index Earning Revision (Nov): Toyota Motor, SoftBank, Rakuten, Kioxia, Sony Financial

Japan

TERUMO CORPORATION is a manufacturer and supplier of pharmaceuticals and medical tools and equipment.  The Company's products include health foods, transfusion and infusion equipment, disposable medical supply, clinical testing systems, artificial organs, and electronic thermometers.  Terumo markets the products through its subsidiaries and sales offices in the US, Europe, and Asia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Terumo Corp (4543 JP)

Shin Etsu Chemical (4063 JP): The Current Playbook

The offering will likely be priced on 4 February. The average large Japanese placement tends to generate positive returns.

Arun George

Kandenko (1942 JP): A US$1.0 Billion Secondary Offering

The timing of the placement after upgrading full-year forecasts will not be well-received. The offering as a percentage of out. shares and ADV are...

Arun George

Shin Etsu Chemical (4063 JP): A US$1.0 Billion Secondary Offering

The offering as a percentage of outstanding shares and ADV is small compared to recent large placements. An ongoing JPY100 billion share buyback...

Arun George

M-Japan Index Earning Revision (Nov): Toyota Motor, SoftBank, Rakuten, Kioxia, Sony Financial

We analyzed M-Japan's consensus for Nov 2025 and highlighted changes of EPS in Toyota Motor (7203 JP), SoftBank (9984 JP), Rakuten (4755 JP),...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Shin Etsu Chemical (4063 JP): The Current Playbook

The offering will likely be priced on 4 February. The average large Japanese placement tends to generate positive returns.

Arun George

Kandenko (1942 JP): A US$1.0 Billion Secondary Offering

The timing of the placement after upgrading full-year forecasts will not be well-received. The offering as a percentage of out. shares and ADV are...

Arun George

Shin Etsu Chemical (4063 JP): A US$1.0 Billion Secondary Offering

The offering as a percentage of outstanding shares and ADV is small compared to recent large placements. An ongoing JPY100 billion share buyback...

Arun George

Nihon Kohden (6849 JP): Stable Japan, Growing US; ¥5B Share Buyback Plan Augurs Well

​Nihon Kohden reaffirms revenue guidance for FY26, with focus on growth in North America and sustainable long-term prospects. The share buyback...

Tina Banerjee

M-Japan Index Earning Revision (Nov): Toyota Motor, SoftBank, Rakuten, Kioxia, Sony Financial

We analyzed M-Japan's consensus for Nov 2025 and highlighted changes of EPS in Toyota Motor (7203 JP), SoftBank (9984 JP), Rakuten (4755 JP),...

Ke Yan, CFA, FRM

Nihon Kohden reaffirms revenue guidance for FY26, with focus on growth in North America and sustainable long-term prospects. The share buyback...